LIVZON PHARMA [01513] Announces Approval for Voluntary Public Tender Offer in Vietnam

Bulletin Express

03/06

Livzon Pharmaceutical Group Inc. (LIVZON PHARMA [01513]) announced that its wholly-owned overseas subsidiary, LIAN SGP HOLDING PTE. LTD., received official approval from the State Securities Commission of Vietnam for a proposed voluntary public tender offer for shares in Imexpharm Corporation (IMP), a listed company in Vietnam.

The company’s Board of Directors had previously passed resolutions on 22 May 2025 and 30 December 2025, approving the relevant proposals for the acquisition of equity interests in IMP. Under these resolutions, LIAN SGP HOLDING PTE. LTD. was authorized to submit an application to proceed with the tender offer.

Livzon Pharmaceutical Group Inc. highlighted that the contemplated transaction remains subject to uncertainties, including market changes and further approval requirements. The company will comply with all applicable regulations and disclosure obligations throughout the process, advising investors to exercise caution when dealing in its securities.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1148646401"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1148646401\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1148646401?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-06 19:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148646401","market":"us","top_or_hot":-1,"title":"LIVZON PHARMA [01513] Announces Approval for Voluntary Public Tender Offer in Vietnam","media":"Bulletin Express","content":"<p>Livzon Pharmaceutical Group Inc. (LIVZON PHARMA [01513]) announced that its wholly-owned overseas subsidiary, LIAN SGP HOLDING PTE. LTD., received official approval from the State Securities Commission of Vietnam for a proposed voluntary public tender offer for shares in Imexpharm Corporation (IMP), a listed company in Vietnam.</p>\n<p>The company’s Board of Directors had previously passed resolutions on 22 May 2025 and 30 December 2025, approving the relevant proposals for the acquisition of equity interests in IMP. Under these resolutions, LIAN SGP HOLDING PTE. LTD. was authorized to submit an application to proceed with the tender offer.</p>\n<p>Livzon Pharmaceutical Group Inc. highlighted that the contemplated transaction remains subject to uncertainties, including market changes and further approval requirements. The company will comply with all applicable regulations and disclosure obligations throughout the process, advising investors to exercise caution when dealing in its securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LIVZON PHARMA [01513] Announces Approval for Voluntary Public Tender Offer in Vietnam</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLIVZON PHARMA [01513] Announces Approval for Voluntary Public Tender Offer in Vietnam\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-06 19:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Livzon Pharmaceutical Group Inc. (LIVZON PHARMA [01513]) announced that its wholly-owned overseas subsidiary, LIAN SGP HOLDING PTE. LTD., received official approval from the State Securities Commission of Vietnam for a proposed voluntary public tender offer for shares in Imexpharm Corporation (IMP), a listed company in Vietnam.</p>\n<p>The company’s Board of Directors had previously passed resolutions on 22 May 2025 and 30 December 2025, approving the relevant proposals for the acquisition of equity interests in IMP. Under these resolutions, LIAN SGP HOLDING PTE. LTD. was authorized to submit an application to proceed with the tender offer.</p>\n<p>Livzon Pharmaceutical Group Inc. highlighted that the contemplated transaction remains subject to uncertainties, including market changes and further approval requirements. The company will comply with all applicable regulations and disclosure obligations throughout the process, advising investors to exercise caution when dealing in its securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01513","symbol_name":"丽珠医药","start_time":0,"source_url":"","article_id":"1148646401","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148646401","pubTimestamp":1772796162,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Livzon Pharmaceutical Group Inc. (LIVZON PHARMA [01513]) announced that its wholly-owned overseas subsidiary, LIAN SGP HOLDING PTE. LTD., received official approval from the State Securities...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01513":"丽珠医药"},"translate_title":"丽珠医药[01513]宣布越南自愿公开要约收购获批","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01513":1},"content_text":"Livzon Pharmaceutical Group Inc. (LIVZON PHARMA [01513]) announced that its wholly-owned overseas subsidiary, LIAN SGP HOLDING PTE. LTD., received official approval from the State Securities Commission of Vietnam for a proposed voluntary public tender offer for shares in Imexpharm Corporation (IMP), a listed company in Vietnam.\nThe company’s Board of Directors had previously passed resolutions on 22 May 2025 and 30 December 2025, approving the relevant proposals for the acquisition of equity interests in IMP. Under these resolutions, LIAN SGP HOLDING PTE. LTD. was authorized to submit an application to proceed with the tender offer.\nLivzon Pharmaceutical Group Inc. highlighted that the contemplated transaction remains subject to uncertainties, including market changes and further approval requirements. The company will comply with all applicable regulations and disclosure obligations throughout the process, advising investors to exercise caution when dealing in its securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}